India’s second-largest drugmaker by revenue, Dr. Reddy will sell its U.S. and select territory rights for Zembrace and Tosymra (used for treating migraine), which were...
EquityPandit’s Outlook for Dr. Reddy for the week (May 27, 2019 – May 31,2019) DR. REDDY: DRRDDY Ltd. BSE: 500180| NSE: DRREDDY| ISIN: INE040A01026|...